Results

1–10 of 85 results for Aflibercept

PULSAR Extension: Clinical Improvements Sustained Over 156 Weeks With Aflibercept 8 mg in Patients With Neovascular Age-Related Macular Degeneration
David T.W. Wong, MD, FRCS(C), FASRS
Updates from the Field
2025
Aflibercept 8 mg in Diabetic Macular Edema: 156-Week Results From the PHOTON Extension Study
Eric W Schneider, MD
Updates from the Field
2025
VERONA: End-of-Study Results From a Phase 2 Trial of EYP-1901 (Vorolanib Intravitreal Insert) vs Aflibercept for Diabetic Macular Edema
Yasha S Modi, MD
Updates from the Field
2025
Outcomes of Patients with DME and Baseline BCVA 20/50 or Worse or 20/40 or Better Treated with Aflibercept 8 mg and 2 mg in the Phase 2/3 PHOTON Trial
Diana V Do, MD, FASRS
Updates from the Field
2024
Novel Vascular Endothelial Growth-Factor A (VEGF-A) and Angiopoietin-2 (Ang-2) Bispecific Protein, RO-634, in Comparison to Aflibercept
Mark R. Barakat, MD
Annual Meeting Talks
2022
Effects of Time Since Diagnosis to Intravitreal Aflibercept Injection and Baseline BCVA on Outcomes in CRVO: Post Hoc Analysis of the COPERNICUS and GALILEO Trials
Dilsher S. Dhoot, MD
Annual Meeting Talks
2022
Association Between DRSS Changes and Visual/ Anatomic Outcomes in Patients With Moderately Severe to Severe NPDR: Post Hoc Analysis of PANORAMA
Diana V Do, MD, FASRS
Annual Meeting Talks
2022
Aflibercept Monotherapy vs Initial Bevacizumab Followed by Aflibercept if Needed for Treatment of Center-Involved Diabetic Macular Edema
Chirag D. Jhaveri, MD, FASRS
Annual Meeting Talks
2022
Phase IIIb TALON study of brolucizumab versus aflibercept in a matched treat-and-extend regimen to treat neovascular AMD: 32-week primary outcomes
Carl D. Regillo, MD
Annual Meeting Talks
2022
Prospective Randomized Trial of Treat-and-Extend Intravitreal Aflibercept for Radiation Retinopathy: One-Year Outcomes
Amy C. Schefler, MD FACS FASRS
Annual Meeting Talks
2022